Hepatitis B is an infectious liver disease. It is caused by the hepatitis B virus (HBV). Infections of hepatitis B occur only if the virus is able to enter the blood stream and reach the liver. Once in the liver, the virus reproduces and releases large numbers of new viruses into the bloodstream.
To combat the disease, the body has several defenses. White blood cells, which protect the body from infections, attack and destroy the infected liver cells. The body also produces antibodies which circulate in the blood to destroy the virus and protect against future infections of hepatitis B. During the infection and recovery process, the liver may not function normally causing illness that affects the entire body.
For reasons that are not completely understood, 10 percent of people who develop hepatitis B become carriers of the disease. Their blood remains infected for months, years, sometimes for life. Seventy percent of carriers develop chronic persistent hepatitis B. Most do not appear to be ill. The remaining 30 percent of carriers experience continuous liver disease. This condition often progresses to cirrhosis and then, after 30 to 40 years, possibly to liver cancer. At present, there is no way of curing carriers. The risk of becoming a chronic carrier is related inversely with a person's age when infected. For example, the risk of an infant becoming a carrier is 90-95% whereas the risk of an adult becoming a carrier is 3-10%.
There are other kinds of viral hepatitis such as hepatitis A, hepatitis C, hepatitis D (delta), and hepatitis E. These diseases and the viruses that cause them are not related to hepatitis B even though they also affect the liver.
The incubation period (the time between initial contact with the virus and onset of the disease) for hepatitis B ranges from 45 to 180 days with an average of 60 to 90 days. The length of the incubation period depends on the amount of virus to which a person is exposed. Exposure to a large dose of virus results in a short incubation period.
In 2006, the Public Health Agency of Canada (PHAC) reported the incidence of HBV as 2.0 cases for every 100,000 or about 650 cases reported annually in Canada, but many more cases probably remain unreported. Incidence of the disease varies from region to region but has been declining due to increasing use of the vaccine. The incidence rate higher among males than females and is highest in the 30-39 years age group. Analysis of donated blood indicates that about 0.15 percent of donors carry the hepatitis B virus, although for patients in a general hospital it can be as high as 0.80 percent. Blood tests also indicate that about 5 percent of people in Canada have had hepatitis B at some point in their lives.
The annual rate of occupational infections has decreased 95% in health care workers since the vaccine became available in 1982.
Blood is the major source of the hepatitis B virus in the workplace. It can also be found in other tissues and body fluids, but in much lower concentrations. The risk of transmission varies according to the specific source. The virus can survive outside the body for at least 7 days and still able to cause infection.
Direct contact with infected blood can transmit the hepatitis B virus through:
To a lesser extent, indirect contact with blood-contaminated surfaces can also transmit the hepatitis B virus. The virus may be stable in dried blood for up to 7 days at 25°C. Hand contact with blood-contaminated surfaces such as laboratory benches, test tubes, or laboratory instruments may transfer the virus to skin or mucous membranes.
Saliva of people with hepatitis B can contain the hepatitis B virus, but in very low concentrations compared with blood. Injections of infected saliva can transmit the virus, so bite injuries can also spread the disease. There are no reports of people getting hepatitis B from mouth contact with infected CPR manikins or mouthpieces of musical instruments.
Hepatitis B is found in semen and vaginal secretions. The virus can be transmitted during unprotected sexual intercourse, and from mother to infant during birth.
Synovial fluid (joint lubricant), amniotic fluid, cerebrospinal fluid, and peritoneal fluid (found in the abdominal cavity) can contain the hepatitis B virus, but the risk of transmission to workers is not known.
Feces, nasal secretions, sputum, sweat, tears, urine, and vomit have not been implicated in the spread of hepatitis B. Unless they are visibly contaminated with blood, the risk of contracting hepatitis B from these fluids in the workplace is practically nonexistent.
Hepatitis B is not transmitted by casual contact. For example, hospital employees who have no contact with blood, blood products, or blood-contaminated fluids are at no greater risk than the general public. However, the virus can spread through intimate contact with carriers in a household setting. Why this happens is not completely understood. Somehow, the virus can find its way into the bloodstream of fellow family members possibly because of frequent physical contact with the small cuts or skin rashes. The virus can also spread through biting and possibly by the sharing of toothbrushes or razors. It is not spread through sneezing, coughing, hand holding, hugging, breastfeeding, sharing eating utensils, water or food.
The risk of acquiring hepatitis B from the workplace depends on the amount of exposure to:
Blood tests show that certain occupational groups have different risks of getting hepatitis B.
| Table 1 |
Risks to Occupational Groups
|Percentage of people having evidence of past hepatitis B infection||Occupational Group|
|High (over 20%)||Pathologists, biochemistry and hematology laboratory personnel, dialysis staff|
|Intermediate (7-20%)||Hospital nurses, laboratory personnel other than those in high risk groups, staff of institutions for the developmentally handicapped, dentists|
|Low (less than 7%)||Administrative hospital staff, medical and dental students, healthy adults|
In general, occupational groups with increased risk include:
In mild cases, the signs and symptoms are those of a minor infection. In severe cases, they are extreme reactions resulting from liver failure. The extent of the illness depends on the original size of the dose of the virus, the route of exposure, and the specific response of the infected individual.
More than half of hepatitis B infections occur and pass without noticeable symptoms. Sometimes, only mild symptoms such as a general discomfort occur. Rarely is medical attention needed. Often, the infection disappears without treatment. In fact, laboratory testing is often the only way of determining whether someone has had hepatitis B.
When symptoms develop, the earliest ones often include a general discomfort, joint pain, abdominal pain, fatigue, lack of appetite, skin rash or possibly nausea, vomiting or other flu-like symptoms.
In relatively few cases, these symptoms are followed by jaundice causing skin and white of eyes to yellow and urine to darken--typical signs of a malfunctioning liver. An accumulation of a waste product, called bilirubin, in the blood causes this yellowish colour. Jaundice and other symptoms usually subside gradually within 3 to 4 weeks and most patients fully recover, in the process becoming immune to the disease.
People with serious cases of hepatitis B require hospitalization. A very small proportion of these patients develop a critical form of the disease called "fulminant" hepatitis B. This condition results from a sudden breakdown of liver function. Fulminant hepatitis B is extremely serious. Over half of the victims of fulminant hepatitis B die from the disease.
Tests are available to detect three types of antigens used to identify the hepatitis B virus. The tests determine if the virus is present in the body tissue or blood. The amount of each type of antigen present indicates how advanced the disease is and how infective the individual has become.
Other tests are available to detect the body's reaction to the viral infection or the body's reaction to vaccination against the virus. These tests work by measuring the number of antibodies present in the blood. Tests also show how effective a vaccine will be.
At present, there is no specific treatment for patients with acute hepatitis B although research is continuing. Physicians commonly recommend that patients with the disease limit their physical activity although they do not necessarily restrict them to bed-rest. They also advise patients to drink clear liquids during the early stages of the infection and to avoid high-protein diets and alcohol. Hospitalization may be required for patients who suffer from severe vomiting and who are unable to maintain adequate nutritional levels. It may also be required to prevent the development of complications.
For chronic infection, there are two standard treatments in Canada. Interferon may be given for short periods and if effective, results in suppression of the virus. Lamivudine can be used the same way or for long-term control of the virus. Other treatments are currently approved for adult patients with chronic HBV infection in the United States. Physicians may do regular monitoring for signs of liver disease progression.
The risk of hepatitis B can be significantly reduced by:
Infection control precautions are the first line of defense to protect workers from hepatitis B and other blood-borne diseases. For this reason, the Laboratory Centre for Disease Control at Health Canada and the United States Department of Health and Human Services developed a uniform approach called "routine practices".
Originally developed for hospitals, routine practices have been adapted to a wide range of workplaces. They apply to all situations where workers have risk of exposure to blood or certain body fluids.
The purpose of routine practices is to prevent exposure to blood-borne diseases transmitted by needlestick accidents or fluid contact with an open wound, non-intact skin, or mucous membranes. Routine practices are to be used in conjunction with other control measures. An example is washing hands whenever gloves are removed or whenever the skin contacts potentially infectious fluids.
Routine practices recommend the use of engineering controls, safe work practices, and personal protective equipment to suit the specific task and workplace.
Engineering controls include the use of equipment to isolate or contain the hazard, such as puncture-resistant containers for disposing of used sharps, or biological cabinets for certain procedures in laboratories.
Safe work practices are required for all tasks involving possible exposure to blood or certain body fluids. They include:
Personal protective equipment provides a barrier to blood and certain body fluids. Equipment recommended by routine practices include:
Please see the OSH Answers document Routine Practices for more information.
Specific routine practices have been developed for:
Hepatitis B vaccines are licensed in Canada. They provide safe, reliable protection from hepatitis B when used either before or immediately after exposure to the virus. Tests show 90 to 95 percent of vaccinations of healthy people result in the development of resistance against hepatitis B. At present, vaccination is the surest way to avoid acquiring hepatitis B as an occupational disease.
Side effects are usually mild with soreness at the injection site being the most commonly reported. Studies show no link between the hepatitis B vaccine and multiple sclerosis, chronic fatigue syndrome, rheumatoid arthritis or Guillain-Barré syndrome. The vaccine may very rarely cause a severe life-threatening, whole-body allergic reaction (anaphylaxis). People with allergies to any hepatitis B vaccine ingredients, for example, yeast, should not receive the vaccine. Check with your health professional for more information.
Protection from the vaccine lasts at least fifteen years. Booster doses are generally not recommended for people with normal immune status.
The National Advisory Committee on Immunization (NACI) recommends the vaccination of people who are at increased risk of contracting hepatitis B because of exposure to the virus in their work. They also recommend vaccination for people who are sexual or household contacts of carriers of hepatitis B.
Since the risk varies from workplace to workplace, institutions should review their situations and develop their own vaccination priorities. Hospital employees who have no contact with blood, blood products, or blood-contaminated body fluids and who are not at risk of needlestick injuries, are at no greater risk of hepatitis B than the general population.
Workers who experience needlestick injuries, splash exposures to blood from carriers, or bite injuries should immediately seek medical attention. In some jurisdictions, local legislation outlines the procedure for treating these injuries.
If the blood is known to contain the hepatitis B virus, and the exposed worker has not been vaccinated or does not have antibodies against hepatitis B, post-exposure immunization is strongly recommended to prevent the development of hepatitis B.
National immunization guidelines recommend post-exposure vaccination when the source of blood is unknown. Vaccination against hepatitis B is usually recommended within seven days of exposure. Depending on the specific circumstance, hepatitis B immunoglobulin is sometimes recommended also. Immunoglobulin is a preparation containing antibodies which attack the hepatitis B virus. It is usually given as quickly as possible, preferably within 24 hours of the incident.
If the worker's blood has antibodies against hepatitis B, or if the contaminated blood is free of virus, further treatment may be unnecessary.
In summary, hepatitis B is a serious occupational concern for workers who may be exposed to blood or certain body fluids. However, the use of routine practices for blood and certain other body fluids, and immunization (complete hepatitis B vaccine series) including post-vaccination testing to document immunity, greatly reduces and can eliminate the risk of hepatitis B.
Document last updated on August 28, 2013